Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2020-12-23 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于召开2021年第一次临时股东大会通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2021 first extraordinary general meeting (临时股东大会) of shareholders for 哈药集团股份有限公司. It includes information about the meeting date, voting methods (including cumulative voting), agenda items such as amendments to the company charter, adjustments to independent director allowances, and election of directors, independent directors, and supervisors. It also contains procedural details for shareholders to attend and vote, including proxy forms and voting instructions. There is no financial data or earnings information, nor is it a report or transcript. The document is clearly an announcement related to a shareholders' meeting, specifically a notice of the meeting and its agenda, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this document is a notice of the meeting and voting procedures rather than the solicitation materials or the actual voting results, it aligns best with Proxy Solicitation & Information Statement (PSI).
2020-12-23 Chinese
独立董事关于调整独立董事津贴的独立意见
Board/Management Information Classification · 95% confidence The document is a formal independent opinion from the independent directors of a company regarding the adjustment of independent director allowances. It references company law and internal company regulations, and it is an opinion supporting a proposal to be submitted to the shareholders' meeting. The document is short (380 characters) and does not contain financial data, earnings, or detailed reports. It is related to board/management matters, specifically about director compensation adjustments. Therefore, it fits best under Board/Management Information (MANG).
2020-12-23 Chinese
独立董事关于提名公司第九届董事会董事候选人的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on the nomination of candidates for the company's ninth board of directors. It discusses the qualifications and compliance of the nominees with relevant regulations and laws, and it concludes with agreement to submit the nominations to the shareholders' meeting for approval. This type of document is related to board or management information, specifically about board nominations and governance matters. It is not a full annual report, audit report, or financial statement, nor is it a voting result or proxy solicitation. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on management nomination, supporting this classification.
2020-12-23 Chinese
哈药集团股份有限公司八届三十九次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed by the board of directors of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) during the 39th meeting of the 8th board. It includes nominations for the 9th board of directors and independent directors, statements of qualifications and independence of the nominees, and details about the adjustment of independent director stipends. The document is focused on board decisions, nominations, and governance matters rather than financial results, audit opinions, or shareholder voting results. It does not contain financial statements or earnings data, nor is it a report publication announcement. The content aligns with announcements related to changes or nominations in the company's board or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is substantial (15,000 characters), indicating it is the full announcement, not a brief notice or certification.
2020-12-23 Chinese
哈药集团股份有限公司八届十六次监事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a supervisory board meeting resolution regarding the nomination of candidates for the next supervisory board. It includes details about the meeting, voting results, and candidate resumes. There is no financial data, no mention of annual or interim reports, earnings, or other financial disclosures. It is a governance-related announcement about board/supervisory personnel changes and nominations. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2020-12-23 Chinese
哈药集团股份有限公司八届三十八次董事会决议公告
Capital/Financing Update Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 regarding the approval of a bank loan application. It details the board meeting date, voting results, and authorization for management to proceed with the loan. There is no financial report, audit, or earnings data presented. The content is about a financing decision, specifically a loan application, which fits the category of Capital/Financing Update (CAP). The document length is short and focused on this financing update, not an announcement of a report or regulatory filing. Therefore, the classification is CAP with high confidence.
2020-12-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.